About
Olaparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of certain cancers, particularly those with BRCA gene mutations. It works by blocking PARP enzymes, which are involved in DNA repair. By inhibiting PARP, olaparib prevents cancer cells with impaired DNA repair pathways (like those with BRCA mutations) from repairing their DNA, leading to cell death. This targeted therapy is crucial in managing specific types of ovarian, breast, pancreatic, and prostate cancers, improving progression-free survival in eligible patients. Its mechanism of action exploits the concept of synthetic lethality, where the combination of a PARP inhibitor and a pre-existing DNA repair defect in cancer cells leads to their selective demise while sparing healthy cells.
Uses
- Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Adjuvant treatment of germline BRCA-mutated HER2-negative high-risk early breast cancer.
- Treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma.
- Treatment of metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations.
Directions For Use
Take this medicine orally as directed by your doctor, usually twice daily, with or without food. Swallow the tablets whole; do not chew, crush, or split them.
Benefits
- Targets specific cancer cells with DNA repair defects.
- Improves progression-free survival in various cancers.
- Offers a targeted therapy option for BRCA-mutated cancers.
- Available as an oral formulation, enhancing convenience.
- Can be used as maintenance therapy to prevent recurrence.
- Effective in certain metastatic settings.
Side Effects
- Nausea
- Fatigue
- Vomiting
- Anemia
- Diarrhea
- Decreased appetite
- Abdominal pain
- Headache
- Dysgeusia (taste disturbance)
- Myelosuppression (low blood counts)
- Rash
- Musculoskeletal pain
Safety Measures
- Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects or interact with the medication.
- Pregnancy - Olaparib can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for 6 months after the last dose.
- Breastfeeding - It is not known if olaparib is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for 1 month after the last dose.
- Liver - Use with caution in patients with hepatic impairment. Dose adjustments may be necessary based on the severity of liver dysfunction.
- Kidney - Use with caution in patients with renal impairment. Dose adjustments are recommended for moderate or severe renal impairment.
- Lung - Rarely, pneumonitis has been reported. Monitor for new or worsening respiratory symptoms.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!